NASDAQ:GERNGeron Stock Price, Forecast & News

Geron's stock was trading at $1.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GERN stock has increased by 102.9% and is now trading at $2.09. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Geron.

Geron is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Geron.

Geron Co. (NASDAQ:GERN) announced its quarterly earnings data on Thursday, May, 28th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.04. The biopharmaceutical company had revenue of $0.05 million for the quarter, compared to analysts' expectations of $0.11 million. Geron had a negative net margin of 16,449.23% and a negative return on equity of 52.95%. During the same quarter last year, the business earned ($0.05) EPS. View Geron's earnings history.

5 brokerages have issued twelve-month price objectives for Geron's stock. Their forecasts range from $3.00 to $4.00. On average, they expect Geron's stock price to reach $3.60 in the next twelve months. This suggests a possible upside of 72.2% from the stock's current price. View analysts' price targets for Geron.

Media headlines about GERN stock have been trending extremely negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Geron earned a media sentiment score of -4.3 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the company's share price in the next few days. View the latest news about Geron.

Some companies that are related to Geron include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Amarin (AMRN), TransEnterix (TRXC), Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), Dynavax Technologies (DVAX), Anavex Life Sciences (AVXL), Puma Biotechnology (PBYI), Advanced Micro Devices (AMD) and Chesapeake Energy (CHK).

Geron trades on the NASDAQ under the ticker symbol "GERN."

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GERN stock can currently be purchased for approximately $2.09.

Geron has a market capitalization of $424.93 million and generates $460,000.00 in revenue each year. The biopharmaceutical company earns $-68,550,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Geron employs 45 workers across the globe.

The official website for Geron is www.geron.com.

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]